The observation of IL-38 and IL-37 deficiency in brain tissue from individuals with autism, along with their significant anti-inflammatory effects, suggests that these cytokines may serve as viable therapeutic targets for autism spectrum disorder (12, 91). This evidence concerns the gene IL37 and autism spectrum disorder.